A Pilot Study on the Use of Seysara for Rosacea

Status Completed

Clinical Trial Summary

This is a prospective, parallel group, randomized, investigator-blinded pilot study. Approximately 100 subjects will be randomized at a 3:1 ratio to Seysara (sarecycline) at a weight-based dose per label or Centrum Adult Multivitamin to take by mouth daily. The study is comprised of 5 visits: screening, baseline, week 4, week 8, and week 12. Investigators will perform rosacea IGA (Investigator Global Assessment,) inflammatory lesion count, record adverse events and con meds, and ask each subject to complete a DLQI (Dermatology Life Quality Index.)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04555525
Study type	Interventional
Source	Derm Research, PLLC
Contact
Status	Completed
Phase	Phase 4
Start date	April 15, 2019
Completion date	October 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03064438` - Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea	Phase 2
Active, not recruiting	`NCT05108025` - DMT310-005 Topical in the Treatment of Acne Rosacea	Phase 2
Completed	`NCT02147691` - Finacea 15% and Brimonidine 0.33% Gel in the Treatment of Rosacea - A Pilot Study	Phase 4
Completed	`NCT02270411` - Inflammatory Cells From Various Pathologies
Recruiting	`NCT04214483` - A Pilot Study to Explore the Role of Gut Flora in Acne
Completed	`NCT00041977` - Determine the Effect of Administering Periostat(R) Twice Daily on Patients With Acne Rosacea	Phase 3
Completed	`NCT03003104` - DMT210 Topical Gel in the Treatment of Acne Rosacea	Phase 2
Completed	`NCT00580723` - Effects of PRK 124 Lotion in Acne Rosacea	Phase 1/Phase 2